Assembly Biosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ASMB | 2137.HK | ABUS | VIR | ENTA | AVIR | |
|---|---|---|---|---|---|---|
| Market cap | 404.57M | 739.58M | 622.30M | 1.99B | 310.19M | 357.71M |
| P/E (TTM) | 19.1 | — | 5.1 | — | — | — |
| Forward P/E | -7.7 | -2.0 | -24.6 | -4.8 | -4.5 | -3.0 |
| Price/book | 1.3 | 0.3 | 3.1 | 2.1 | 3.1 | 1.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −37.96% | −44.59% | −15.84% | +107.78% | −5.04% | +28.70% |
| Today | −0.25% | 0.00% | +4.64% | +4.90% | +2.70% | +6.95% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ASMB news ›Assembly Biosciences officer proposes $50.9K stock sale
Palantir Reports Q3 2026 U.S. Comm Revenue Growth of 148% Y/Y and Revenue Growth of 96% Y/Y; Raises FY 2026 Revenue Guidance to 91% Y/Y Growth and U.S. Comm Revenue Guidance to 143% Y/Y, Crushing Consensus Expectations Aehr Test Systems…
Comparing Assembly Biosciences (ASMB) & Its Peers
Posted by Sarita Garza on Nov 2nd, 2026 Assembly Biosciences (NASDAQ:ASMB – Get Free Report) is one of 897 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Assembly…
Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus
Palantir Reports Q3 2026 U.S. Comm Revenue Growth of 148% Y/Y and Revenue Growth of 96% Y/Y; Raises FY 2026 Revenue Guidance to 91% Y/Y Growth and U.S. Comm Revenue Guidance to 143% Y/Y, Crushing Consensus Expectations Aehr Test Systems…
Assembly Biosciences Announces Two Phase 1a ABI-6250 Posters to Be Presented at The Liver Meeting 2026
Assembly Biosciences will present new Phase 1a data for ABI-6250 at The Liver Meeting® 2026 in November. The ABI-6250 program presents Phase 1a data for treating chronic HDV infection and cholestatic liver diseases. Assembly Biosciences…
Assembly Biosciences, Inc. Presents Positive Phase 1a Safety, Tolerability And Target Engagement Data For ABI-6250 At AASLD The Liver Meeting
marketscreener.com announced that two posters featuring new Phase 1a data from its ABI-6250 program will be presented at The Liver Meeting® 2026, the annual
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net2
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.